Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Elicera Therapeutics AB. (10/5/20). "Press Release: Elicera Therapeutics Completes Oversubscribed Share Issue and Secures 13,2 MSEK in Financing".

Organisations Organisation Elicera Therapeutics AB
  Organisation 2 University of Uppsala
Products Product cancer immunotherapy (immuno-oncology, I-O)
  Product 2 venture capital
Index term Index term Elicera Therapeutics–SEVERAL: investment, 202010 first financing round SEK13.2m share issue
Person Person El-Mosleh, Jamal (Elicera Therapeutics 202010– CEO before Immunicum AB 200709– CEO)
     


Elicera Therapeutics announced today that it has completed its first share issue and secured 13,2 MSEK in financing to launch unique immuno-oncology company based on groundbreaking research by professor Magnus Essand's research group at Uppsala University. Jamal El-Mosleh is announced as Elicera's CEO.

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses


Read the press release in Swedish:
Download press release (pdf)
[ https://assets.website-files.com/5e85ca7e8347401d65425175/5f79c0da34c371e7c3b909b2_Pressmeddelande%20Elicera%20Therapeutics%20201005%20-%20Genomförd%20finansiering.pdf ]


   
Record changed: 2021-03-23

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Elicera Therapeutics AB


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner Bionnale 2021 Digital Event 650x80px




» top